Hormone Rx May Protect Women With Breast Cancer Gene

Patients with BRCA mutations cut their odds for malignancy when taking estrogen, study found

By Amanda Gardner
HealthDay Reporter

Related Encyclopedia • Adenocarcinoma of the Lung and Brain Metastases • Amenorrhea • Amniocentesis • Amniocentesis and CVS More... Related Healthscout Videos High Energy Beauty.. Silent Killer Urgent Matters Brainy Baby More... Related Animations • Breast Reduction • Breast Self-Exam Video • Colon Cancer • Erectile Dysfunction More... Related Drug Information • Actonel • Detrol LA • Diflucan • Ditropan XL More... Related News Articles • Genetics Linked to Early Sexual Activity in Kids • Scientists May Know How Lung Cancer Spreads • Teen Birth Rates Higher in States Where Religion Is Widespread • Blood Test for Breast Cancer More...

TUESDAY, Sept. 23 (HealthDay News) -- Postmenopausal women carrying breast cancer-linked BRCA gene mutations who took hormone replacement therapy actually reduced their risk for breast cancer, researchers report.

The study's authors called the finding "reassuring."

Text Continues Below

---

"I have no reservation about recommending HRT to my patients who have a [BRCA] mutation and who have had an oopherectomy [removal of ovaries] and, particularly, young women with surgical menopause," stated Dr. Steven Narod, senior author of the study and chair of breast cancer research at Women's College Hospital in Toronto. "I feel completely, absolutely, 100 percent comfortable in recommending HRT to BRCA carriers."

The study was published in the Sept. 23 issue of the Journal of the National Cancer Institute.

In a prepared statement, Dr. Amos Pines, immediate past president of the International Menopause Society (IMS), said the results support "the IMS view that HRT in the early postmenopausal period is safe and may be prescribed without concerns when needed."

Other commentators, however, approached the subject more conservatively, including IMS Secretary General Dr. Regine Sitruk-Ware.

"Given the limitations of the design and size of the study, caution is still recommended for the use of HRT in women who are carriers of a genetic mutation that expose them to a higher risk of breast cancer in their life," Sitruk-Ware said, also in a prepared statement.

Another expert agreed.

"These observational studies are small and have misled before," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "I would still advise my patients who have a mutational BRCA status, if at all possible, to use as little exogenous estrogen as possible and for as little time as possible."

Some 3 percent of invasive cancers can be attributed to either a BRCA 1 or BRCA 2 gene mutation, which elevate a woman's lifetime risk of developing breast cancer to 60 percent to 80 percent. The National Cancer Institute puts the lifetime risk of developing breast cancer for an average American woman at 12.7 percent.

Page:  1 | 2 | Next >>